ArticleThe Journal of experimental medicine2023
Myeloid-like B cells boost emergency myelopoiesis through IL-10 production during infection.
Article in The Journal of experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Experimental robustness and reproducibility of the murine cecal ligation and puncture sepsis model.Intensive care medicine experimental · 2026Article
- Erythropoietin exposure disrupts B cell development and drives the emergence of myeloid-biased biphenotypic progenitors.Stem cell reports · 2026Article
- Conventional and Alternative B Lymphopoiesis: Multiple Roads to Immunity.Stem cell reviews and reports · 2026Review
- Therapeutic potential of Angelica sinensis derivatized carbon dots in ameliorating chemotherapy-induced anemia.Journal of molecular histology · 2025Article
- Diverse developmental pathways of lymphoid conventional dendritic cells with distinct tissue distribution and function.Science advances · 2025Article
- Article
- The IL-33/ST2 axis is protective against acute inflammation during the course of periodontitis.Nature communications · 2024Article
- An early regulatory mechanism of hyperinflammation by restricting monocyte contribution.Frontiers in immunology · 2024Article
- Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.Biomolecules · 2023Review
- Loss of B1 and marginal zone B cells during ovarian cancer.Cellular immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergency myelopoiesis (EM) is a hematopoietic response against systemic infections that quickly supplies innate immune cells. As lymphopoiesis is strongly suppressed during EM, the role of lymphocytes in that process has not received much attention. Here, we found that myeloid-like B cells (M-B cells), which express myeloid markers, emerge in the bone marrow (BM) after the induction of EM. M-B cells were mainly derived from pre-B cells and preferentially expressed IL-10, which directly stimulates hematopoietic progenitors to enhance their survival and myeloid-biased differentiation. Indeed, lacking IL-10 in B cells, blocking IL-10 in the BM with a neutralizing antibody, and deleting the IL-10 receptor in hematopoietic progenitors significantly suppressed EM, which failed to clear microbes in a cecal ligation and puncture model. Thus, a distinct B cell subset generated during infection plays a pivotal role in boosting EM, which suggests the on-demand reinforcement of EM by adaptive immune cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.